Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report

Arterioscler Thromb Vasc Biol. 2024 Jul;44(7):1646-1657. doi: 10.1161/ATVBAHA.124.320797. Epub 2024 May 2.

Abstract

Background: Trem2 (triggering receptor on myeloid cells 2), a surface lipid receptor, is expressed on foamy macrophages within atherosclerotic lesions and regulates cell survival, proliferation, and anti-inflammatory responses. Studies examining the role of Trem2 in atherosclerosis have shown that deletion of Trem2 leads to impaired foamy macrophage lipid uptake, proliferation, survival, and cholesterol efflux. Thus, we tested the hypothesis that administration of a Trem2 agonist antibody (AL002a) to atherogenic mice would enhance macrophage survival and decrease necrotic core formation to improve plaque stability.

Methods: To model a therapeutic intervention approach, atherosclerosis-prone mice (Ldlr [low-density lipoprotein receptor]-/-) were fed a high-fat diet for 8 weeks, then transitioned to treatment with AL002a or isotype control for an additional 8 weeks while continuing on a high-fat diet.

Results: AL002a-treated mice had increased lesion size in both the aortic root and whole mount aorta, which correlated with an expansion of plaque macrophage area. This expansion was due to increased macrophage survival and proliferation in plaques. Importantly, plaques from AL002a-treated mice showed improved features of plaque stability, including smaller necrotic cores, increased fibrous caps, and greater collagen deposition. Single-cell RNA sequencing of whole aorta suspensions from isotype- and AL002a-treated atherosclerotic mice revealed that Trem2 agonism dramatically altered foamy macrophage transcriptome. This included upregulation of oxidative phosphorylation and increased expression of collagen genes. In vitro studies validated that Trem2 agonism with AL002a promoted foamy macrophage oxidized low-density lipoprotein uptake, survival, and cholesterol efflux.

Conclusions: Trem2 agonism expands atherosclerotic plaque macrophages by promoting cell survival and proliferation but improves features of plaque stability by rewiring foamy macrophage function to enhance cholesterol efflux and collagen deposition.

Keywords: anti-inflammatory agents; cell proliferation; cholesterol; collagen; macrophages.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aortic Diseases / genetics
  • Aortic Diseases / metabolism
  • Aortic Diseases / pathology
  • Aortic Diseases / prevention & control
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / genetics
  • Atherosclerosis* / metabolism
  • Atherosclerosis* / pathology
  • Atherosclerosis* / prevention & control
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Diet, High-Fat
  • Disease Models, Animal*
  • Foam Cells* / drug effects
  • Foam Cells* / metabolism
  • Foam Cells* / pathology
  • Male
  • Membrane Glycoproteins* / agonists
  • Membrane Glycoproteins* / genetics
  • Membrane Glycoproteins* / metabolism
  • Mice
  • Mice, Inbred C57BL*
  • Mice, Knockout*
  • Necrosis
  • Plaque, Atherosclerotic*
  • Receptors, Immunologic* / agonists
  • Receptors, Immunologic* / genetics
  • Receptors, Immunologic* / metabolism
  • Receptors, LDL / deficiency
  • Receptors, LDL / genetics
  • Receptors, LDL / metabolism

Substances

  • Receptors, Immunologic
  • Trem2 protein, mouse
  • Membrane Glycoproteins
  • Receptors, LDL